臺灣博碩士論文加值系統

目的：
本研究主要探討中藥萃取物大黃素於高尿酸血症及痛風的大鼠模型之治療效果。目前國內外有關高尿酸血症及痛風的診斷及治療大多是以西醫臨床評估及西醫藥物治療為主。因為系統性的評估及大量的醫療數據使西醫治療高尿酸血症及痛風普遍獲得民眾的信任。然而臨床上仍有部分民眾對西醫的藥物有不良反應，轉而尋求中醫治療。回顧中醫文獻及臨床案例的觀察可發現，中醫在治療高尿酸血症及痛風具有潛在療效。然而，缺乏科學數據的評估及臨床前研究的案例使民眾對中醫的治療保持懷疑。是故，設計一中藥治療的臨床前研究，以取得更多中藥治療高尿酸血症及痛風的數據，有其必要性及迫切性。
方法：
本研究藉由腹腔注射Potassium Oxonate來誘導大鼠產生高血尿酸。並且藉由比較陽性對照組、陰性對照組、西藥治療組及三種不同濃度的大黃素治療組來觀測大黃素降低血清尿酸的功效。
結果：
與正常對照組相比，中 (30 mg / kg)、高劑量 (50 mg / kg)的Emodin顯著降低血清尿酸濃度(P<0.05)，使尿酸濃度與控制組相比無顯著差異，達到治療高尿酸血症的療效。FEUA數值的上升證明Emodin具有促進尿酸排泄的功效。
結論：
Emodin可降低血清尿酸濃度達到治療高尿酸血症及痛風的療效。結果得到了血清尿酸、FEUA的測量數值支持。我們的數據可能在治療痛風和其他高尿酸血症的臨床實踐中具有潛在價值。

Background:
The study aims to explore the therapeutic effect of a Chinese herbal extract, emodin, in a rat model of hyperuricemia and gout. At present, the diagnosis and treatment of hyperuricemia and gout are mostly based on clinical evaluation of western medicine and Western medicine treatment at home and abroad. Because of systematic evaluation and a large amount of medical data, western medicine treatment of hyperuricemia and gout has generally won the public’s trust. However, in clinical practice, there are still some patients who have adverse reactions to Western medicine and turn to Chinese medicine as an alternative. A review of TCM literature and clinical case observations shows that the application of TCM has potential curative effects in the treatment of hyperuricemia and gout. However, lack of evaluation of scientific data and cases of pre-clinical studies has led the public to remain skeptical about the treatment of TCM. Therefore, it is crucial and urgent to design a preclinical study/research of Chinese medicine treatment to obtain more convincing data on the treatment of hyperuricemia and gout with Chinese medicine.
Methods:
In this study, rats were induced to produce hyperuricemia by intraperitoneal injection of Potassium Oxonate. By comparing the positive control group, negative control group, western medicine treatment group and three different concentrations of emodin treatment group, the observation of the efficacy of emodin in reducing serum uric acid can be thus made.
Results:
Compared with the vehicle control plate, the middle and high concentrations of Emodin significantly reduced the serum uric acid level (P<0.05), so that there was no significant difference between the uric acid concentration and the control group, achieving the curative effect of treating hyperuricemia. The increase in FEUA value proves that Emodin has the effect of promoting uric acid excretion.
Conclusions:
Emodin can reduce serum uric acid concentration to achieve the effect of treating hyperuricemia and gout. The results were supported by the measured values of serum uric acid and FEUA. Our data may have potential value in clinical practice in the treatment of gout and other hyperuricemias.

第一章 前言 1
研究目的和背景 1
第二章 文獻探討 3
第一節 高尿酸血症及痛風的西醫文獻 3
第二節 痛風在中醫會統典籍的相關文獻探討 10
第三節 中藥治療痛風及高尿酸血症的文獻 15
第四節 中藥萃取物Emodin的文獻探討 22
第五節 高尿酸血症及痛風的動物模型的文獻探討 23
第三章 材料與方法 28
第一節 Chemicals and reagents 28
第二節 Animals and treatment 29
第三節 Biochemical analysis 30
第四節 檢測方法 30
第五節 結果評估 32
第四章 結果 33
第一節 Allopurinol、各劑量Emodin對血清尿酸、液尿酸、血清Creatinine、尿液Creatinine以及FEUA的影響 33
第二節 Allopurinol、各劑量Emodin對Xanthine oxidase活性的影響 37
第三節 Allopurinol、各劑量Emodin對血清GOT、GPT的影響 38
第四節 Allopurinol、各劑量Emodin對血清IL-1ß、IL-6和TNF-α的影響 41
第五節 Allopurinol、各劑量Emodin對血清及尿液OSM的影響 45
第六節 Allopurinol、各劑量Emodin對MSU誘導結晶性關節炎之影響 47
第七節 Allopurinol、各劑量Emodin對高尿酸血症大鼠腎臟、肝臟和足踝組織病理學的影響 48
第五章 討論 51
第六章 結論 54
附錄 63
作者簡歷 66

1.Dalbeth, N., et al., Gout. The Lancet, 2021. 397(10287): p. 1843-1855.
2.Ragab, G., M. Elshahaly, and T. Bardin, Gout: An old disease in new perspective - A review. Journal of Advanced Research, 2017. 8(5): p. 495-511.
3.Singh, J.A. and A. Gaffo, Gout epidemiology and comorbidities. Semin Arthritis Rheum, 2020. 50(3S): p. S11-S16.
4.Johnson, R.J., et al., Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases, 2018. 71(6): p. 851-865.
5.Hansildaar, R., et al., Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatology, 2021. 3(1): p. E58-E70.
6.Grassi W, D.A.R., Clinical features of gout. Reumatismo, 2012.
7.Chen-Xu, M., et al., Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol, 2019. 71(6): p. 991-999.
8.Singh, J.A., S.G. Reddy, and J. Kundukulam, Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol, 2011. 23(2): p. 192-202.
9.Kuo, C.F., et al., Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol, 2015. 11(11): p. 649-62.
10.Kim, J.W., et al., Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015. Rheumatol Int, 2017. 37(9): p. 1499-1506.
11.Kuo, C.F., et al., Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther, 2015. 17(1): p. 13.
12.Kuo, C.F., et al., Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis, 2015. 74(4): p. 661-7.
13.Zobbe, K., et al., Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford), 2019. 58(5): p. 836-839.
14.Fathallah-Shaykh, S.A. and M.T. Cramer, Uric acid and the kidney. Pediatr Nephrol, 2014. 29(6): p. 999-1008.
15.Abhishek., A., E. Roddy., and M. Doherty., Gout - a guide for the general and acute physicians. Clin Med (Lond), 2017. 17: p. 54-59.
16.Zhang, W., et al., EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2006. 65(10): p. 1301-11.
17.Richette, P., et al., 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases, 2020. 79(1): p. 31-38.
18.Hainer BL, M.E., Wilkes RT, Diagnosis, treatment, and prevention of gout. Am Fam Physician, 2014.
19.Abhishek Abhishek, E.R., Michael Doherty Gout - a guide for the general and acute physicians. Clin Med (Lond), 2017: p. 54-59.
20.Danve, A., S.T. Sehra, and T. Neogi, Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol, 2021. 35(4): p. 101723.
21.Ramasamy, S.N., et al., Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf, 2013. 36(10): p. 953-80.
22.Hasegawa, A. and R. Abe, Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res, 2020. 9.
23.White, W.B., et al., Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 2018. 378(13): p. 1200-1210.
24.徐芹庭, 細說黃帝內經. 第1版 ed. 2000, 臺北市 :: 聖環圖書. 3冊 :.
25.張仲景, 金匱要略精義. 再版 ed., 台北市 :: 文光. 355面 ;.
26.巢元方, 巢氏諸病源候論. 三版 ed. 1996, 臺北縣新店市 :: 國立中國醫藥研究所. 203面 ;.
27.朱震亨, 丹溪心法. 初版 ed., 台北市 :: 五洲. 922面 ;.
28.朱震亨, 格致余論. 第1版 ed. 2018, 北京 :: 中國醫藥科技出版社. [11], 91面 ;.
29.王燾, 外臺秘要. 台北市 :: 文光. 3冊[1142, 106面] ;.
30.張介賓, 景岳全書. 台北市 :: 台聯國風. 1408面 ;.
31.李梴, 醫學入門. 台北市 :: 台聯國風. 645面 ;.
32.龔廷賢, 萬病回春. 第1版 ed. 1984, 北京市 :: 人民衛生. [14], 496面 ;.
33.張璐, 張氏醫通. 第1版 ed. 1963, 上海 :: 上海科學技術. 44, 1054面 ;.
34.喻嘉言, 醫門法律. 1975, 台北市 :: 新文豐出版. 2冊 ;.
35.林珮琴, (新校本)類證治裁. 初版 ed., 台北市 :: 旋風. 9, 616面 ;.
36.Chen, L.Q., et al., The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review. Frontiers in Pharmacology, 2021. 11: p. 24.
37.Luis-Rodriguez, D., et al., Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. Rheumatology (Oxford), 2021. 60(1): p. 371-379.
38.Azab, A., A. Nassar, and A.N. Azab, Anti-Inflammatory Activity of Natural Products. Molecules, 2016. 21(10).
39.Liu, X.Y., et al., Research Progress of Chinese Herbal Medicine Intervention in Renal Interstitial Fibrosis. Front Pharmacol, 2022. 13: p. 900491.
40.Kimura, Y., D. Tsukui, and H. Kono, Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Int J Mol Sci, 2021. 22(22).
41.Perez-Torres, I., et al., Oxidative Stress, Plant Natural Antioxidants, and Obesity. Int J Mol Sci, 2021. 22(4).
42.Liu, Y.F., et al., The Effects of Modified Simiao Decoction in the Treatment of Gouty Arthritis: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med, 2017. 2017: p. 6037037.
43.Huang, M.C., et al., Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study. J Ethnopharmacol, 2015. 176: p. 9-16.
44.Wang Xing, X.N., L I Hong-Lei, Chen Zhen, Y U Wan, Study on mechanism of Fangji Huangqi Decoction on hypouricemic effect and renal protection in hyperuricemia mice. Zhongguo Zhong Yao Za Zhi, 2020.
45.Xie, Y., et al., Wutou decoction ameliorates experimental rheumatoid arthritis via regulating NF-kB and Nrf2: Integrating efficacy-oriented compatibility of traditional Chinese medicine. Phytomedicine, 2021. 85: p. 153522.
46.Chi, X., et al., Chinese herbal medicine for gout: a review of the clinical evidence and pharmacological mechanisms. Chin Med, 2020. 15: p. 17.
47.Zhang, K.H., et al., Investigation of the Effects and Mechanisms of Dendrobium loddigesii Rolfe Extract on the Treatment of Gout. Evidence-Based Complementary and Alternative Medicine, 2020. 2020: p. 10.
48.Chen, Y., et al., Total saponins from dioscorea septemloba thunb reduce serum uric acid levels in rats with hyperuricemia through OATP1A1 up-regulation. J Huazhong Univ Sci Technolog Med Sci, 2016. 36(2): p. 237-242.
49.Zeng, J.X., et al., Antigout Effects of Plantago asiatica: Xanthine Oxidase Inhibitory Activities Assessed by Electrochemical Biosensing Method. Evid Based Complement Alternat Med, 2018. 2018: p. 1364617.
50.Wu, X.H., et al., Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine. J Ethnopharmacol, 2015. 162: p. 362-8.
51.Zhang, H.J., et al., Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. J Ethnopharmacol, 2017. 203: p. 304-311.
52.Liu, L.M., et al., The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats. Food Chem Toxicol, 2014. 70: p. 179-84.
53.Wang, Y., et al., (1)H NMR and MS based metabolomics study of the therapeutic effect of Cortex Fraxini on hyperuricemic rats. J Ethnopharmacol, 2016. 185: p. 272-81.
54.Shi, D.H., et al., Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors. Eur J Med Chem, 2014. 75: p. 289-96.
55.Park, M.Y., H.J. Kwon, and M.K. Sung, Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. Biosci Biotechnol Biochem, 2009. 73(4): p. 828-32.
56.Dong, X., et al., Aloe-emodin: A review of its pharmacology, toxicity, and pharmacokinetics. Phytother Res, 2020. 34(2): p. 270-281.
57.Bai, J., et al., Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a. Invest New Drugs, 2020. 38(2): p. 229-245.
58.Li-Weber, M., Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Letters, 2013. 332(2): p. 304-312.
59.Chao, H.W., et al., Emodin protected against retinal ischemia insulted neurons through the downregulation of protein overexpression of beta-catenin and vascular endothelium factor. BMC Complement Med Ther, 2020. 20(1): p. 338.
60.Mei, H., et al., Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes. J Inflamm (Lond), 2020. 17: p. 26.
61.Shen, C.Y., et al., Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery. British Journal of Pharmacology, 2017. 174(11): p. 1395-1425.
62.Leung, S.W., et al., Neuroprotective Effects of Emodin against Ischemia/Reperfusion Injury through Activating ERK-1/2 Signaling Pathway. Int J Mol Sci, 2020. 21(8).
63.Dong, X., et al., Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics. Phytother Res, 2016. 30(8): p. 1207-18.
64.Monisha, B.A., N. Kumar, and A.B. Tiku, Emodin and Its Role in Chronic Diseases. Adv Exp Med Biol, 2016. 928: p. 47-73.
65.Maiuolo, J., et al., Regulation of uric acid metabolism and excretion. International Journal of Cardiology, 2016. 213: p. 8-14.
66.Fan, C.Y., et al., Betaine supplementation protects against high-fructose-induced renal injury in rats. Journal of Nutritional Biochemistry, 2014. 25(3): p. 353-362.
67.Murugaiyah, V. and K.L. Chan, Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents. Journal of Ethnopharmacology, 2009. 124(2): p. 233-239.
68.Kishnani, P.S., et al., Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). Veterinary Pathology, 2001. 38(1): p. 83-91.
69.Dhouibi, R., et al., Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance. Life Sci, 2021. 268: p. 118998.
70.Hong, F., et al., High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. Int J Mol Sci, 2020. 21(6).
71.Guan, J., et al., A novel mouse model of hyperuricemia and gouty nephropathy. Chin Med J (Engl), 2020. 133(16): p. 2012-2014.
72.Torres, R., et al., Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Annals of the Rheumatic Diseases, 2009. 68(10): p. 1602-1608.
73.Hyndman, D., S. Liu, and J.N. Miner, Urate Handling in the Human Body. Curr Rheumatol Rep, 2016. 18(6): p. 34.
74.Wang, A., et al., Metabolic Factors Mediate the Association Between Serum Uric Acid to Serum Creatinine Ratio and Cardiovascular Disease. J Am Heart Assoc, 2021. 10(23): p. e023054.